Andrea L. Ruth Joins AI/ML Innovations Inc. as Head of Quality, Clinical and Regulatory Affairs
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Andrea L. Ruth as Head of Quality, Clinical, and Regulatory Affairs. With over 20 years of experience in medical device and biotechnology sectors, Ruth brings expertise in regulatory compliance and quality systems implementation.
Ruth, who holds a Master of Management, has extensive experience working with global regulatory bodies including FDA and EMA. Her role will focus on maintaining safety, efficacy, and compliance standards as AIML expands its AI-driven healthcare solutions portfolio.
AIML operates in artificial intelligence and machine learning fields, focusing on digital health and wellbeing solutions. The company owns Quantum Sciences , NeuralCloud Solutions Inc., and has strategic partnerships with Health Gauge Inc. (95.2% owned), Tech2Heal (11.11% owned), and AI Rx Inc. (70% owned).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) ha nominato Andrea L. Ruth come Responsabile della Qualità, Affari Clinici e Regolamentari. Con oltre 20 anni di esperienza nei settori dei dispositivi medici e della biotecnologia, Ruth porta con sé competenze nella conformità regolatoria e nell'implementazione di sistemi di qualità.
Ruth, che possiede un Master in Management, ha una vasta esperienza nel lavorare con organismi regolatori globali, tra cui FDA ed EMA. Il suo ruolo si concentrerà sul mantenimento degli standard di sicurezza, efficacia e conformità mentre AIML espande il suo portafoglio di soluzioni sanitarie basate sull'AI.
AIML opera nei campi dell'intelligenza artificiale e dell'apprendimento automatico, focalizzandosi su soluzioni per la salute digitale e il benessere. La società possiede Quantum Sciences, NeuralCloud Solutions Inc. e ha partnership strategiche con Health Gauge Inc. (95,2% di proprietà), Tech2Heal (11,11% di proprietà) e AI Rx Inc. (70% di proprietà).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) ha nombrado a Andrea L. Ruth como Jefa de Calidad, Asuntos Clínicos y Regulatorios. Con más de 20 años de experiencia en los sectores de dispositivos médicos y biotecnología, Ruth aporta experiencia en cumplimiento normativo e implementación de sistemas de calidad.
Ruth, que posee un Máster en Gestión, tiene amplia experiencia trabajando con organismos regulatorios globales, incluyendo la FDA y la EMA. Su papel se centrará en mantener los estándares de seguridad, eficacia y cumplimiento mientras AIML expande su cartera de soluciones de salud impulsadas por IA.
AIML opera en los campos de la inteligencia artificial y el aprendizaje automático, enfocándose en soluciones de salud digital y bienestar. La compañía posee Quantum Sciences, NeuralCloud Solutions Inc., y tiene asociaciones estratégicas con Health Gauge Inc. (95,2% de propiedad), Tech2Heal (11,11% de propiedad) y AI Rx Inc. (70% de propiedad).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)는 Andrea L. Ruth를 품질, 임상 및 규제 업무 책임자로 임명했습니다. 의료기기 및 생명공학 분야에서 20년 이상의 경험을 가진 Ruth는 규제 준수 및 품질 시스템 구현에 대한 전문성을 가지고 있습니다.
경영학 석사 학위를 소지한 Ruth는 FDA 및 EMA를 포함한 글로벌 규제 기관과의 협력 경험이 풍부합니다. 그녀의 역할은 AIML이 AI 기반 헬스케어 솔루션 포트폴리오를 확장하는 동안 안전성, 효과성 및 준수 기준을 유지하는 데 집중할 것입니다.
AIML은 인공지능 및 머신러닝 분야에서 활동하며 디지털 건강 및 웰빙 솔루션에 중점을 둡니다. 이 회사는 Quantum Sciences, NeuralCloud Solutions Inc.를 소유하고 있으며, Health Gauge Inc. (95.2% 소유), Tech2Heal (11.11% 소유) 및 AI Rx Inc. (70% 소유)와 전략적 파트너십을 맺고 있습니다.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) a nommé Andrea L. Ruth au poste de Responsable de la Qualité, des Affaires Cliniques et Réglementaires. Forte de plus de 20 ans d'expérience dans les secteurs des dispositifs médicaux et de la biotechnologie, Ruth apporte une expertise en conformité réglementaire et en mise en œuvre de systèmes de qualité.
Ruth, qui détient un Master en Management, possède une vaste expérience de collaboration avec des organismes réglementaires mondiaux, y compris la FDA et l'EMA. Son rôle se concentrera sur le maintien des normes de sécurité, d'efficacité et de conformité alors qu'AIML élargit son portefeuille de solutions de santé basées sur l'IA.
AIML opère dans les domaines de l'intelligence artificielle et de l'apprentissage automatique, en se concentrant sur des solutions de santé numérique et de bien-être. L'entreprise détient Quantum Sciences, NeuralCloud Solutions Inc. et a des partenariats stratégiques avec Health Gauge Inc. (95,2 % de propriété), Tech2Heal (11,11 % de propriété) et AI Rx Inc. (70 % de propriété).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) hat Andrea L. Ruth zur Leiterin Qualität, Klinik und Regulierungsangelegenheiten ernannt. Mit über 20 Jahren Erfahrung in den Bereichen Medizinprodukte und Biotechnologie bringt Ruth Fachkenntnisse in der regulatorischen Konformität und der Implementierung von Qualitätssystemen mit.
Ruth, die einen Master in Management hält, hat umfassende Erfahrungen in der Zusammenarbeit mit globalen Regulierungsbehörden, darunter FDA und EMA. Ihre Rolle wird sich darauf konzentrieren, Sicherheits-, Wirksamkeits- und Compliance-Standards aufrechtzuerhalten, während AIML sein Portfolio an KI-gesteuerten Gesundheitslösungen erweitert.
AIML ist im Bereich der künstlichen Intelligenz und des maschinellen Lernens tätig und konzentriert sich auf digitale Gesundheits- und Wohlfühl-Lösungen. Das Unternehmen besitzt Quantum Sciences, NeuralCloud Solutions Inc. und hat strategische Partnerschaften mit Health Gauge Inc. (95,2 % Eigentum), Tech2Heal (11,11 % Eigentum) und AI Rx Inc. (70 % Eigentum).
- Strategic hire brings 20+ years of medical device and biotechnology regulatory expertise
- Strengthens capability to navigate FDA, EMA, and international regulatory requirements
- Enhances operational capabilities for product approvals and clinical operations
- None.
▪ Accomplished Leader to Oversee Quality and Compliance Across AIML's Global Operations
▪ Strengthens AIML's Commitment to Providing Reliable and Innovative AI-Powered Healthcare Solutions
VANCOUVER, BC / ACCESS Newswire / February 5, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Andrea L. Ruth, M.S., as Head of Quality, Clinical, and Regulatory. Ms. Ruth's deep expertise in quality assurance, clinical operations, and regulatory compliance will be instrumental in ensuring AIML's continued excellence in delivering innovative healthcare solutions.
With over two decades of experience in the medical device and biotechnology sectors, Ms. Ruth has established herself as a leader in navigating complex regulatory landscapes and implementing robust quality systems. She has previously held key leadership roles, where she was integral in driving regulatory approvals and clinical development for cutting-edge medical technologies. Her work spans global regulatory jurisdictions, including the FDA, EMA, and other international health authorities.
Paul Duffy, CEO of AIML, commented: "We are thrilled to welcome Andrea Ruth to our leadership team. Her exceptional track record in regulatory compliance, coupled with her commitment to quality and innovation, makes her a perfect fit for AIML. As we expand our portfolio of AI-driven healthcare solutions, Andrea's expertise will be critical in maintaining the highest standards of safety, efficacy, and compliance."
Peter Kendall, President of AIML, added: "Andrea brings unparalleled expertise and a proven ability to navigate the ever-evolving regulatory environment. Her leadership will not only enhance our operational capabilities but also reinforce AIML's position as a trusted innovator in digital health solutions. We are confident that her contributions will help us deliver even greater value to our stakeholders."
Andrea Ruth commented: "I am delighted to join AIML at such an exciting time in its journey. The Company's commitment to harnessing cutting-edge AI and machine learning technologies to revolutionize healthcare aligns perfectly with my passion for driving innovation while maintaining the highest standards of quality and compliance. I look forward to working with the talented AIML team to bring transformative solutions to market."
Andrea Ruth holds a Master of Management and has a history of successfully leading cross-functional teams to secure product approvals and streamline clinical operations. She is recognized for her ability to bridge the gap between technical development and regulatory requirements, ensuring products meet the stringent demands of the healthcare industry.
Mark Orsmond, Executive Chairman of AIML, added: "Andrea's addition to our leadership team underscores AIML's commitment to operational excellence and patient safety. Her proven ability to navigate complex regulatory environments and champion quality systems will be a cornerstone of our success as we bring transformative technologies to market."
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.
About AI/ML Innovations Inc. https://aiml-innovations.com/
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its acquisition of Quantum Sciences Ltd. (
On behalf of the Board of Directors:
Mark Orsmond, Executive Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Andrea L. Ruth's role at AIML (AIMLF) and when was she appointed?
What ownership percentage does AIML (AIMLF) have in its key partnerships?
What regulatory bodies does Andrea L. Ruth have experience with at AIML (AIMLF)?
What are AIML's (AIMLF) current trading markets and symbols?
